menu
    • menu
    [{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"PPAR gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SignPath Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SignPath Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral spray","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGC Pharmaceuticals \/ Malta Enerprises","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Malta Enerprises"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Curcumin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Swiss PharmaCan","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Swiss PharmaCan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Swiss PharmaCan \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swiss PharmaCan \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Curcumin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"PLT Health Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PLT Health Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLT Health Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Artemisinin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharma"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Curcumin","moa":"PTK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Immix Biopharma \/ Johnson & Johnson"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lutein","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Vascarta","sponsor":"CUNY","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Collaboration","leadProduct":"Gemcitabine","moa":"||DNA polymerase\/RR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ CUNY","highestDevelopmentStatusID":"4","companyTruncated":"Vascarta \/ CUNY"}]

    Find Clinical Drug Pipeline Developments & Deals for Curcumin

    Menu

    Curcumin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vascarta

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Vascarta

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine,Curcumin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CUNY

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vascarta and CUNY Collaborate to Improve Chemotherapy Efficacy and Safety

                            Details : The collaboration aims to advance the clinical development of a therapy that links anti-cancer agents, such as Gemzar (gemcitabine), with curcumin to enhance the effectiveness in treating cancer.

                            Product Name : Gemzar

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Gemcitabine,Curcumin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CUNY

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BioAsia
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutein,Zeaxanthin,Curcumin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bausch + Lomb Launches Blink NutriTears Supplement For Dry Eyes In US

                            Details : Blink NutriTears is a clinically proven nutritional supplement developed to help relieve dry eye symptoms. It contains a proprietary blend of lutein, zeaxanthin, curcumin, & vitamin D.

                            Product Name : Blink NutriTears

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 03, 2024

                            Lead Product(s) : Lutein,Zeaxanthin,Curcumin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immix Biopharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Immix Biopharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcumin,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Johnson & Johnson

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabected...

                            Details : One cycle of IMX-110 (curcumin) produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug).

                            Product Name : IMX-110

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 20, 2022

                            Lead Product(s) : Curcumin,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Johnson & Johnson

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hempstreet

                            India arrow
                            BioAsia
                            Not Confirmed

                            Hempstreet

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : MGC Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector

                            Details : Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.

                            Product Name : CimetrA

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 07, 2022

                            Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : MGC Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PLT Health Solutions

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            PLT Health Solutions

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcumin,Moringa Oleifera,Murraya Koenigii

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PLT Announces New Clinical Studies that Shed Light on the Non-Stimulant Thermogenic Benefits of Slendacor® We...

                            Details : Slendacor, a patented combination of three extracts of turmeric, drumstick leaves, and curry leaves showed up to a 15.2% increase in resting energy expenditure at Day 7, reshape fat metabolism & improve cardiometabolic health while helping people lose we...

                            Product Name : Slendacor

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Curcumin,Moringa Oleifera,Murraya Koenigii

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Swiss PharmaCan

                            Switzerland arrow
                            BioAsia
                            Not Confirmed

                            Swiss PharmaCan

                            Switzerland arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : MGC Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COV...

                            Details : The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three time...

                            Product Name : ArtemiC

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2021

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : MGC Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MGC Pharma Gets CDSCO Approval to Import its Nanoparticle Micellar Formulation, CimetrA for Testing to Treat C...

                            Details : MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswel...

                            Product Name : CimetrA

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 02, 2021

                            Lead Product(s) : Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Malta Enerprises

                            Deal Size : $3.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta

                            Details : The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.

                            Product Name : ArtemiC

                            Product Type : Small molecule

                            Upfront Cash : $3.7 million

                            December 22, 2020

                            Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Malta Enerprises

                            Deal Size : $3.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update

                            Details : Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.

                            Product Name : ArtemiC

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2020

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed

                            MGC Pharmaceuticals

                            Australia arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MGC Pharmaceuticals Expands ArtemiC™ Phase II Clinical Trial on COVID-19 Patients in Israel and India

                            Details : The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients...

                            Product Name : ArtemiC

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2020

                            Lead Product(s) : Artemisinin,Curcumin,Frankincense

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth